Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section 1 Introduction
- Section 2 Research ethics
- 4 Improving the informed consent process in research with substance-abusing participants
- 5 Ethical considerations in genetic research with children affected by parental substance abuse
- 6 Protecting privacy in genetic research on alcohol dependence and other addictions
- 7 Certificates of Confidentiality: Uses and limitations as protection for genetic research on addiction
- 8 Ethical issues in human genomic databases in addiction research
- 9 Should addiction researchers accept funding derived from the profits of addictive consumptions?
- 10 Ethical issues related to receiving research funding from the alcohol industry and other commercial interests
- Section 3 Translating addiction research
- Section 4 Conclusions
- Index
- References
10 - Ethical issues related to receiving research funding from the alcohol industry and other commercial interests
from Section 2 - Research ethics
Published online by Cambridge University Press: 05 September 2012
Edited by
Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section 1 Introduction
- Section 2 Research ethics
- 4 Improving the informed consent process in research with substance-abusing participants
- 5 Ethical considerations in genetic research with children affected by parental substance abuse
- 6 Protecting privacy in genetic research on alcohol dependence and other addictions
- 7 Certificates of Confidentiality: Uses and limitations as protection for genetic research on addiction
- 8 Ethical issues in human genomic databases in addiction research
- 9 Should addiction researchers accept funding derived from the profits of addictive consumptions?
- 10 Ethical issues related to receiving research funding from the alcohol industry and other commercial interests
- Section 3 Translating addiction research
- Section 4 Conclusions
- Index
- References
Summary
Introduction
Using terms of justification such as “corporate social responsibility” and “partnerships with the public health community,” the alcohol, tobacco, and gambling industries (mainly large producers, trade associations, interest groups, and social aspects organizations) fund a variety of scientific activities that involve addiction scientists or overlap with their work. In addition, the pharmaceutical industry funds clinical trials and supports other activities related to scientific research, such as the preparation of manuscripts and the sponsorship of lectures by speakers who investigate their products. The aim of this chapter is to evaluate the ethical challenges that have emerged from industry involvement in addiction science, particularly in relation to genetic research.
At the center of the ethical challenges are issues of trust, credibility, and conflict of interest. Trust in the addiction research world can be affected when commercial interests are perceived to outweigh health considerations. The credibility of scientific findings may be affected when evidence emerges that industry-sponsored research is flawed, biased, or methodologically weak. Conflict of interest is a situation in which the researcher has a personal or financial interest that may be put above the integrity of the research being conducted. After reviewing the extent of industry involvement in addiction research, we discuss the moral hazards of research funding from commercial interests, and offer ways in which individual investigators as well as professional organizations can work to minimize these risks.
- Type
- Chapter
- Information
- Genetic Research on AddictionEthics, the Law, and Public Health, pp. 139 - 154Publisher: Cambridge University PressPrint publication year: 2012
References
2011 www.abmrf.org/about_us.asp
2011 www.abmrf.org/unique_partnership.asp
2011 www.abmrf.org/grants2.asp
2011 www.abmrf.org/medical_advisory_council.asp
2011 www.abmrf.org/board_of_trustees.asp
2007 Assessing whether to receive funding support from tobacco, alcohol, gambling and other dangerous consumption industriesAddiction 102 1027CrossRefGoogle ScholarPubMed
2003 Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse eventsJAMA: The Journal of the American Medical Association 290 921CrossRefGoogle ScholarPubMed
2006 Diageo, University College Dublin and the integrity of alcohol science: It’s time to draw the line between public health and public relationsAddiction 101 1375Google ScholarPubMed
2009 Alcohol research and the alcoholic beverage industry: Issues, concerns and conflicts of interestAddiction 104 34CrossRefGoogle ScholarPubMed
2010 Vested interests, addiction research and public policyAddiction 105 4CrossRefGoogle ScholarPubMed
2010 Alcohol policies out of context: Drinks industry supplanting government role in alcohol policies in Sub-Saharan AfricaAddiction 105 22CrossRefGoogle ScholarPubMed
1998 Why review articles on the effects of passive smoking reach different conclusionsJAMA: The Journal of the American Medical Association 279 1566CrossRefGoogle ScholarPubMed
2003 Scope and impact of financial conflicts of interest in biomedical research: A systematic reviewJAMA: The Journal of the American Medical Association 289 454CrossRefGoogle ScholarPubMed
1996 Influences on the quality of published drug studiesInternational Journal of Technology Assessment in Health Care 12 209CrossRefGoogle ScholarPubMed
2007 Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than othersPLoS Medicine 4 184CrossRefGoogle ScholarPubMed
2004 Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trialsCanadian Medical Association Journal 170 477Google ScholarPubMed
2009 Financial and intellectual conflicts of interest: Confusion and clarityCurrent Opinion in Critical Care 15 583CrossRefGoogle ScholarPubMed
2005 The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interestLancet 365 531Google ScholarPubMed
2010 Selling addictions: Similarities in approaches between Big Tobacco and Big BoozeAustralasian Medical Journal 3 325CrossRefGoogle Scholar
2011 www.bu.edu/alcohol-forum
2011 www.bu.edu/alcohol-forum/archives-april-2010-april-2011
2008 Everyone’s a little bit biased (even physicians)JAMA: The Journal of the American Medical Association 299 2893CrossRefGoogle Scholar
2005 Nicotine addiction through a neurogenomic prism: Ethics, public health, and smokingNicotine and Tobacco Research 7 181CrossRefGoogle ScholarPubMed
2012 Addiction Neuroethics: The Promises and Perils of Neuroscience Research on AddictionNew YorkCambridge University PressGoogle Scholar
2008 Nordic Studies on Alcohol and Drugs 25 316
2003 A social science perspective on gifts to physicians from industryJAMA: The Journal of the American Medical Association 290 252CrossRefGoogle ScholarPubMed
1986 Source of funding and outcome of clinical trialsJournal of General Internal Medicine 1 155CrossRefGoogle ScholarPubMed
2008 Impugning the integrity of medical science: The adverse effects of industry influenceJAMA: The Journal of the American Medical Association 299 1833CrossRefGoogle ScholarPubMed
2004 An EU Code of Ethics for Socio-Economic ResearchBrighton, UKInstitute for Employment Studieswww.respectproject.org/ethics/412ethics.pdfGoogle Scholar
2000 The uncertainty principle and industry-sponsored researchLancet 356 635CrossRefGoogle ScholarPubMed
2004
2011 www.galloresearch.org/about.htm
2011 www.galloresearch.org/board.htm
2011 www.erab.org/asp2/about_erab/index.asp?doc_id=428
2011 www.erab.org/asp2/about_erab/board_of_directors.asp
2011 www.erab.org/asp2/about_erab/advisory_board.asp
2011 www.erab.org/documents/research_grants/Research_funded_03_-_10.pdf
2007 The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: A meta-analysisAddiction 102 815CrossRefGoogle ScholarPubMed
2007 http://opa.faseb.org/pages/Advocacy/coi/Toolkit.htm
1999 Evaluation of conflict of interest in economic analyses of new drugs used in oncologyJAMA: The Journal of the American Medical Association 282 1453CrossRefGoogle Scholar
2004 Relationship between conflicts of interest and research resultsJournal of General Internal Medicine 19 51CrossRefGoogle ScholarPubMed
2004 www.genewatch.org/pub-507666
2011 Unconscious conflict of interest: A Jewish perspectiveJournal of Medical Ethics 37 402CrossRefGoogle ScholarPubMed
2009 A common standard for conflict of interest disclosure in addiction journalsAddiction 104 1779CrossRefGoogle ScholarPubMed
2010 To prove this is the industry’s best hope: Big tobacco’s support of research on the genetics of nicotine addictionAddiction 105 974CrossRefGoogle ScholarPubMed
2002 The genetics of tobacco use: Methods, findings and policy implicationsTobacco Control 11 119CrossRefGoogle ScholarPubMed
2010 Being more realistic about the public health impact of genomic medicinePLoS Medicine 7CrossRefGoogle ScholarPubMed
www.roche.com/sci-genetictesting.pdf 2012
2001 www.icap.org/LinkClick.aspx?fileticket=jMev%2FS7JOa4%3D&tabid=75
2009 Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer researchCancer 115 2783CrossRefGoogle ScholarPubMed
2012 Global alcohol producers, science, and policy: The case of the International Center for Alcohol PoliciesAmerican Journal of Public Health 102 80CrossRefGoogle ScholarPubMed
2003 All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-givingAmerican Journal of Bioethics 3 39CrossRefGoogle ScholarPubMed
2002 Association between competing interests and authors’ conclusions: Epidemiological study of randomised clinical trials published in the BMJBritish Medical Journal (Clinical Research Ed.) 325 249CrossRefGoogle ScholarPubMed
2003 Pharmaceutical industry sponsorship and research outcome and quality: Systematic reviewBritish Medical Journal (Clinical Research Ed.) 326 1167CrossRefGoogle ScholarPubMed
2008 Publishing Addiction Science: A Guide for the PerplexedLondon, UKMulti-Science Publishing CompanyGoogle Scholar
2003 Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applicationsBritish Medical Journal (Clinical Research Ed.) 326 1171CrossRefGoogle ScholarPubMed
2011 Addiction Neuroethics: The Ethics of Addiction Neuroscience Research and TreatmentChennai, IndiaAcademic PressGoogle Scholar
2008 Publishing Addiction Science: A Guide for the PerplexedLondon, UKMulti-Science Publishing CompanyGoogle Scholar
2004 www.boston.com/news/local/articles/2004/11/06/gambling_industry_link_to_harvard_draws_questions/ 2012
2004 An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophreniaControlled Clinical Trials 25 598CrossRefGoogle ScholarPubMed
2004 Self-interest, automaticity, and the psychology of conflict of interestSocial Justice Research 17 189CrossRefGoogle Scholar
2011 www.ncrg.org/about-ncrg
2007 Adverse effects of inhaled corticosteroids in funded and nonfunded studiesArchives of Internal Medicine 167 2047CrossRefGoogle ScholarPubMed
2010 Civil war in alcohol policy: Northern versus southern EuropeAddiction Research and Theory 18 389CrossRefGoogle Scholar
2005 Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatryAmerican Journal of Psychiatry 162 1957CrossRefGoogle ScholarPubMed
2009 www.plosmedicine.org/static/competing.action
2006 The extent of the “prevention paradox” in alcohol problems as a function of population drinking patternsAddiction 101 84CrossRefGoogle ScholarPubMed
2008 How pharmaceutical industry funding affects trial outcomes: causal structures and responsesSocial Science and Medicine 66 1909CrossRefGoogle ScholarPubMed
2008 Pharmaceutical company funding and its consequences: a qualitative systematic reviewContemporary Clinical Trials 29 109CrossRefGoogle ScholarPubMed
2008 Corporate philanthropy, lobbying, and public health policyAmerican Journal of Public Health 98 2123CrossRefGoogle ScholarPubMed
2007 Influence of drug company authorship and sponsorship on drug trial outcomesBritish Journal of Psychiatry 191 82CrossRefGoogle ScholarPubMed
2007 Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort studyBritish Medical Journal (Clinical Research Ed.) 335 1202CrossRefGoogle ScholarPubMed
2001 The association between funding by commercial interests and study outcome in randomized controlled drug trialsFamily Practice 18 565CrossRefGoogle ScholarPubMed
2009 Big tobacco and the human genome: Driving the scientific bandwagon?Genomics, Society and Policy 5 1CrossRefGoogle Scholar
- 1
- Cited by